{"disease":{"id":"myeloproliferative-diseases","name":"myeloproliferative diseases"},"drugs":{"marketed":[{"drug_id":"gleevec","indication_name":"Myelodysplastic/myeloproliferative diseases with re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"imatinib","indication_name":"Myelodysplastic/myeloproliferative diseases with re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00003816","title":"Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":361,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT00544115","title":"Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":260,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT01572662","title":"Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":201,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02661035","title":"Allo HSCT Using RIC for Hematological Diseases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT06727383","title":"CAR-NK Cells Production and Expansion From Patients With Lympho or Myeloproliferative Disorders and From Healthy Donors","phase":"NA","overall_status":"UNKNOWN","enrollment_count":140,"lead_sponsor_name":"European Institute of Oncology","has_results":false},{"nct_id":"NCT00619879","title":"Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies","phase":"","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Ann & Robert H Lurie Children's Hospital of Chicago","has_results":false},{"nct_id":"NCT01444742","title":"Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT01787552","title":"A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03434730","title":"Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT00053989","title":"NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT00281814","title":"Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant","phase":"","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"The Cleveland Clinic","has_results":false},{"nct_id":"NCT01375140","title":"Ruxolitinib and Lenalidomide for Patients With Myelofibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02267278","title":"Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT00611351","title":"Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"University of Nebraska","has_results":true},{"nct_id":"NCT02410551","title":"Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT01875237","title":"Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}